ALS
NewcelX Appoints Jeremy Shefner to Scientific Advisory Board
NewcelX; Jeremy Shefner; Scientific Advisory Board; ALS; AstroRx; neurodegenerative disease; Barrow Neurological Institute; cell therapy; clinical trials
FDA Misses IND Deadline for Coya’s ALS Asset, Citing Resource Constraints
FDA; Coya Therapeutics; IND application; ALS; clinical trial delay; COYA 302; resource shortage
Lilly Strengthens Neuro Pipeline with $45M Deal for QurAlis’ Preclinical ALS and Dementia Treatment
Lilly, QurAlis, ALS, dementia, neurodegenerative diseases, UNC13A, splice-switching antisense oligonucleotide, QRL-204, neuro pipeline, preclinical treatment